Among patients with obstructive sleep apnea using CPAP, pitolisant given at 20 mg and 40 mg reduces excessive daytime sleepiness.

Sleep apnea can have untold consequences even in your waking hours. The good news? The condition is treatable.

Obstructive sleep apnea may increase the risk for Parkinson’s disease, but early intervention with continuous positive airway ...

This review included 30 studies to analyze the potential for prolonged life in patients who use CPAP to treat obstructive sleep apnea.

IHL-42X is designed to treat OSA by targeting its underlying pathophysiology. An oral fixed-dose combination of dronabinol and acetazolamide, IHL-42X is currently advancing through the RePOSA Phase ...

Fact checked by Nick Blackmer A growing body of evidence suggests that there may be a link between sleep apnea and ...

For millions of Americans who struggle with sleep apnea, using a CPAP machine might feel like an inconvenience — the mask ...

Obstructive sleep apnea (OSA) may raise the risk for Parkinson’s disease (PD), but early use of continuous positive airway pressure (CPAP) may mediate that effect, a large observational study ...

Compared with placebo, pitolisant 20 and 40 mg had a greater treatment response for residual excessive daytime sleepiness in patients with OSA treated with CPAP. Pitolisant reduces residual ...

Having a continuous positive airway pressure (CPAP) designed for travel offers convenience and ensures uninterrupted treatment of sleep apnea while you are on the road and even camping. However, ...